SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-23-120777
Filing Date
2023-11-22
Accepted
2023-11-22 16:30:18
Documents
16
Period of Report
2023-11-15
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm2331382d1_8ka.htm   iXBRL 8-K/A 34932
2 EXHIBIT 16.1 tm2331382d1_ex16-1.htm EX-16.1 4036
7 GRAPHIC tm2331382d1_ex16-1img001.jpg GRAPHIC 8245
8 GRAPHIC tm2331382d1_ex16-1img002.jpg GRAPHIC 5728
  Complete submission text file 0001104659-23-120777.txt   280127

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20231115.xsd EX-101.SCH 3303
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20231115_def.xml EX-101.DEF 26897
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20231115_lab.xml EX-101.LAB 36508
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20231115_pre.xml EX-101.PRE 25521
10 EXTRACTED XBRL INSTANCE DOCUMENT tm2331382d1_8ka_htm.xml XML 4908
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38302 | Film No.: 231433881
SIC: 2834 Pharmaceutical Preparations